145 related articles for article (PubMed ID: 38430269)
1. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
[TBL] [Abstract][Full Text] [Related]
2. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study.
Shen L; Qi H; Chen S; Cao F; Xie L; Wu Y; Ma W; Song Z; Yuan H; Zhang T; Li D; Wen X; Chen Q; Li W; Zhang X; Fan W
Cancer Immunol Immunother; 2020 Sep; 69(9):1713-1724. PubMed ID: 32333081
[TBL] [Abstract][Full Text] [Related]
3. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
Gu C; Wang X; Wang K; Xie F; Chen L; Ji H; Sun J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272564
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
5. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria.
Rong G; Bai W; Dong Z; Wang C; Lu Y; Zeng Z; Qu J; Lou M; Wang H; Gao X; Chang X; An L; Li H; Chen Y; Hu KQ; Yang Y
PLoS One; 2015; 10(4):e0123065. PubMed ID: 25849963
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the combination of cryoablation with surgical resection of hepatic tumors.
Cha C; Lee FT; Rikkers LF; Niederhuber JE; Nguyen BT; Mahvi DM
J Gastrointest Surg; 2001; 5(2):206-13. PubMed ID: 11331484
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.
Zeng Z; Shi F; Zhou L; Zhang MN; Chen Y; Chang XJ; Lu YY; Bai WL; Qu JH; Wang CP; Wang H; Lou M; Wang FS; Lv JY; Yang YP
PLoS One; 2011; 6(9):e23621. PubMed ID: 21912640
[TBL] [Abstract][Full Text] [Related]
10. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
11. Serum Cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with Tumor Features, Clinical Response, and Survival.
Zhang L; Zhang S; Han Z; Liu Z; Xu Y; Li X; Miao G; Niu L
Tohoku J Exp Med; 2024 Mar; 262(2):133-141. PubMed ID: 37914283
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
Afzal MZ; Mercado RR; Shirai K
J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520
[TBL] [Abstract][Full Text] [Related]
14. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
15. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
[TBL] [Abstract][Full Text] [Related]
17. CT-guided percutaneous cryoablation for palliative therapy of gastric cancer liver metastases.
Chang X; Wang Y; Yu HP; Zhang WH; Yang XL; Guo Z
Cryobiology; 2018 Jun; 82():43-48. PubMed ID: 29679550
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous cryoablation of ovarian cancer metastasis to the liver: initial experience in 13 patients.
Gao W; Guo Z; Zhang X; Wang Y; Zhang W; Yang X; Yu H
Int J Gynecol Cancer; 2015 Jun; 25(5):802-8. PubMed ID: 25793465
[TBL] [Abstract][Full Text] [Related]
19. PD-1 monoclonal antibodies enhance the cryoablation-induced antitumor immune response: a breast cancer murine model research.
Yu ZP; Sun XW; He YP; Gu J; Jin Y
Int J Hyperthermia; 2023; 40(1):2164625. PubMed ID: 36966808
[TBL] [Abstract][Full Text] [Related]
20. Survival analysis of patients with recurrent or metastatic soft tissue sarcoma who were treated by cryoablation: A real-world retrospective study.
Wu Q; Li J; Yang W
J Cancer Res Ther; 2021 Dec; 17(7):1736-1741. PubMed ID: 35381747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
